Hans-Gottfried Genieser

Hans-Gottfried Genieser

Auto-generated profile, based on publicly available information

Hans-Gottfried Genieser

BIOLOG Life Science Institute Forschungslabor und Biochemica-Vertrieb GmbH, 28199 Bremen, Germany

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2002 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
JEJorrit M. Enserink
Jorrit M. Enserink
ACAnne E. Christensen
Anne E. Christensen
JRJohan de Rooij
Johan de Rooij
MTMiranda van Triest
Miranda van Triest
FSFrank Schwede
Frank Schwede
JBJohannes L. Bos
Johannes L. Bos

1 September 2003 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
ACAnne E. Christensen
Anne E. Christensen
FSFrode Selheim
Frode Selheim
JRJohan de Rooij
Johan de Rooij
SDSarah Dremier
Sarah Dremier
FSFrank Schwede
Frank Schwede
SDStein Doskeland
Stein Doskeland
Little is known about the relative role of cAMP-dependent protein kinase (cAPK) and guanine exchange factor directly activated by cAMP (Epac) as mediators of cAMP action. We tested cAMP analogs for ability to selectively activate Epac1 or cAPK and discriminate between the binding sites of Epac and of cAPKI and cAPKII. We found that commonly used cAMP analogs, like 8-Br-cAMP and 8-pCPT-cAMP, activate Epac and cAPK equally as well as cAMP, i.e. were full agonists. In contrast, 6-modified cAMP analogs, like N6-benzoyl-cAMP, were inefficient Epac activators and full cAPK activators. Analogs modified in the 2′-position of the ribose induced stronger Epac1 activation than cAMP but were only partial agonists for cAPK. 2′-O-Alkyl substitution of cAMP improved Epac/cAPK binding selectivity 10–100-fold. Phenylthio substituents in position 8, particularly with MeO- or Cl- in p-position, enhanced the Epac/cAPK selectivity even more. The combination of 8-pCPT- and 2′-O-methyl substitutions improved the Epac/cAPK binding selectivity about three orders of magnitude. The cAPK selectivity of 6-substituted cAMP analogs, the preferential inhibition of cAPK by moderate concentrations of Rp-cAMPS analogs, and the Epac selectivity of 8-pCPT-2′-O-methyl-cAMP was also demonstrated in intact cells. Using these compounds to selectively modulate Epac and cAPK in PC-12 cells, we observed that analogs selectively activating Epac synergized strongly with cAPK specific analogs to induce neurite outgrowth. We therefore conclude that cAMP-induced neurite outgrowth is mediated by both Epac and cAPK.

1 March 2003 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
GKGuoxin Kang
Guoxin Kang
JJJamie W. Joseph
Jamie W. Joseph
OCOleg G. Chepurny
Oleg G. Chepurny
MMMarie Monaco
Marie Monaco
MWMichael B Wheeler
Michael B Wheeler
GHGeorge G. Holz
George G. Holz
The second messenger cAMP exerts powerful stimulatory effects on Ca2+ signaling and insulin secretion in pancreatic β-cells. Previous studies of β-cells focused on protein kinase A (PKA) as a downstream effector of cAMP action. However, it is now apparent that cAMP also exerts its effects by binding to cAMP-regulated guanine nucleotide exchange factors (Epac). Although one effector of Epac is the Ras-related G protein Rap1, it is not fully understood what the functional consequences of Epac-mediated signal transduction are at the cellular level. 8-(4-chloro-phenylthio)-2′-O-methyladenosine-3′-5′-cyclic monophosphate (8-pCPT-2′-O-Me-cAMP) is a newly described cAMP analog, and it activates Epac but not PKA. Here we demonstrate that 8-pCPT-2′-O-Me-cAMP acts in human pancreatic β-cells and INS-1 insulin-secreting cells to mobilize Ca2+ from intracellular Ca2+ stores via Epac-mediated Ca2+-induced Ca2+ release (CICR). The cAMP-dependent increase of [Ca2+]i that accompanies CICR is shown to be coupled to exocytosis. We propose that the interaction of cAMP and Epac to trigger CICR explains, at least in part, the blood glucose-lowering properties of an insulinotropic hormone (glucagon-like peptide-1, also known as GLP-1) now under investigation for use in the treatment of type-2 diabetes mellitus.

1 April 2008 in Nature Methods
Verified
Journal Article
Closed access
PDF file
HPHeiko Poppe
Heiko Poppe
SRSergei D Rybalkin
Sergei D Rybalkin
HRHolger Rehmann
Holger Rehmann
THThomas R Hinds
Thomas R Hinds
XTXiao-Bo Tang
Xiao-Bo Tang
EBElke Butt
Elke Butt

1 August 2000 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
FSFrank Schwede
Frank Schwede
Erik MarondeErik Maronde
Erik Maronde
HGHans-Gottfried Genieser
Hans-Gottfried Genieser
BJBernd Jastorff
Bernd Jastorff

1 September 1995 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
BGBjorn T Gjertsen
Bjorn T Gjertsen
GMGunnar Mellgren
Gunnar Mellgren
AOAnne Otten
Anne Otten
Erik MarondeErik Maronde
Erik Maronde
HGHans-G. Genieser
Hans-G. Genieser
SDStein Doskeland
Stein Doskeland
Novel (Rp)-cAMPS analogs differed widely in ability to antagonize cAMP activation of pure cAMP-dependent protein kinase I and II and to antagonize actions of cAMP on gene expression, shape change, apoptosis, DNA replication, and protein phosphorylation in intact cells. These differences were related to different abilities of the analogs to stabilize the holoenzyme form relative to the dissociated form of cAMP kinase type I and II. (Rp)-8-Br-cAMPS and (Rp)-8-Cl-cAMPS were the most potent cAMP antagonists for isolated type I kinase and for cells expressing mostly type I kinase, like IPC-81 leukemia cells, fibroblasts transfected with type I regulatory subunit (RI), and primary hepatocytes. It is proposed that (Rp)-8-Br-cAMPS or (Rp)-8-Cl-cAMPS should replace (Rp)-cAMPS as the first line cAMP antagonist, particularly for studies in cells expressing predominantly type I kinase. The phosphorylation of endogenous hepatocyte proteins was affected oppositely by (Rp)-8-Br-cAMPS and increased cAMP, indicating that (Rp)-8-Br-cAMPS inhibited basal cAMP-kinase activity. The inhibition of basal kinase activity was accompanied by enhanced DNA replication, an effect which could be reproduced by microinjected mutant cAMP-subresponsive RI. It is concluded that the basal cAMP-kinase activity exerts a tonic inhibition of hepatocyte replication. (Rp)-8-Br-cAMPS and microinjected RI also desensitized hepatocytes toward inhibition of DNA synthesis by interleukin-1β. This indicates that basal cAMP-kinase activity can have a permissive role for the action of another (interleukin-1β) signaling pathway.